Characteristics of MCL (cyclin D1–positive) and SLL patients included in the study*
| Clinical feature . | MCL n = 30 . | SLL n = 12 . |
|---|---|---|
| Median age, y (range) | 63 (37-88) | 59 (40-90) |
| Sex, n (%) | ||
| Female | 5 (17) | 3 (27) |
| Male | 25 (83) | 8 (63) |
| Performance score, n (%) | ||
| < 70 | 3 (10) | 0 (0) |
| > 70 | 27 (90) | 11 (100) |
| Stage | ||
| I/II | 2 (6) | 2 (18) |
| III/IV | 28 (94) | 9 (82) |
| Serum lactate dehydrogenase, n (%) | ||
| Normal | 21 (70) | 9 (82) |
| Elevated | 9 (30) | 2 (11) |
| No. of extranodal sites, n (%) | ||
| < 2 | 26 (87) | 10 (91) |
| > 2 | 4 (13) | 1 (9) |
| Median survival, y | ||
| OS | 3.0 | |
| EFS | 1.5 | 6.2 |
| Clinical feature . | MCL n = 30 . | SLL n = 12 . |
|---|---|---|
| Median age, y (range) | 63 (37-88) | 59 (40-90) |
| Sex, n (%) | ||
| Female | 5 (17) | 3 (27) |
| Male | 25 (83) | 8 (63) |
| Performance score, n (%) | ||
| < 70 | 3 (10) | 0 (0) |
| > 70 | 27 (90) | 11 (100) |
| Stage | ||
| I/II | 2 (6) | 2 (18) |
| III/IV | 28 (94) | 9 (82) |
| Serum lactate dehydrogenase, n (%) | ||
| Normal | 21 (70) | 9 (82) |
| Elevated | 9 (30) | 2 (11) |
| No. of extranodal sites, n (%) | ||
| < 2 | 26 (87) | 10 (91) |
| > 2 | 4 (13) | 1 (9) |
| Median survival, y | ||
| OS | 3.0 | |
| EFS | 1.5 | 6.2 |
EFS indicates event-free survival.
The characteristics of 6 (of 7) cyclin D1–negative MCL patients have been described previously8 ; the seventh case, without GEP, showed MCL morphology and SOX11 expression consistent with other t(11;14)–negative MCL patients. One of the 12 SLL patients lacked complete clinical data.